Sacutan 97 mg+103 mg (Tablet)
Unit Price: ৳ 120.00 (1 x 10: ৳ 1,200.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Indications
- Reducing risk of cardiovascular death
- Reducing risk of hospitalization for heart failure
- Treatment of symptomatic heart failure
- Administration in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor (sacubitril)
- Contains angiotensin receptor blocker (valsartan)
- Inhibits neprilysin via LBQ657
- Blocks angiotensin II type-1 (AT1) receptor
- Increases levels of peptides degraded by neprilysin
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Recommended starting dose for pediatric heart failure: Refer to Table 1 for the recommended dose
- Dosage titration for pediatric patients less than 40 kg
- Dosage titration for pediatric patients at least 40 kg, less than 50 kg
- Dosage titration for pediatric patients at least 50 kg
Interaction
- Should not be used with an ACEi
- Should not be used with aliskiren in patients with diabetes
- Avoid use with an ARB
- Potential interaction with potassium-sparing diuretics
- Potential interaction with NSAIDs
- Increased risk of lithium toxicity
- Dual blockade of the Renin-Angiotensin-Aldosterone System
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors or aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required in patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Recommended starting dose in patients with severe renal impairment: 24/26 mg twice daily
Precautions & Warnings
- May cause angioedema
- Must not be used in patients with known history of angioedema
- Lowers blood pressure
- May cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium periodically
- Treatment of hyperkalemia may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Starting dose recommendation for severe renal impairment
- Starting dose recommendation for moderate hepatic impairment
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
- Dialysis unlikely to remove the medication
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children